PE20210123A1 - Compuesto de anillo de metillactama y uso farmaceutico del mismo - Google Patents

Compuesto de anillo de metillactama y uso farmaceutico del mismo

Info

Publication number
PE20210123A1
PE20210123A1 PE2020001287A PE2020001287A PE20210123A1 PE 20210123 A1 PE20210123 A1 PE 20210123A1 PE 2020001287 A PE2020001287 A PE 2020001287A PE 2020001287 A PE2020001287 A PE 2020001287A PE 20210123 A1 PE20210123 A1 PE 20210123A1
Authority
PE
Peru
Prior art keywords
pharmaceutical use
methyllactam
same
ring compound
compound
Prior art date
Application number
PE2020001287A
Other languages
English (en)
Spanish (es)
Inventor
Tomoya Miura
Yoshinori Tamatani
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of PE20210123A1 publication Critical patent/PE20210123A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41551,2-Diazoles non condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PE2020001287A 2018-03-01 2019-02-28 Compuesto de anillo de metillactama y uso farmaceutico del mismo PE20210123A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018036307 2018-03-01
PCT/JP2019/007799 WO2019168096A1 (ja) 2018-03-01 2019-02-28 メチルラクタム環化合物及びその医薬用途

Publications (1)

Publication Number Publication Date
PE20210123A1 true PE20210123A1 (es) 2021-01-19

Family

ID=67806229

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2020001287A PE20210123A1 (es) 2018-03-01 2019-02-28 Compuesto de anillo de metillactama y uso farmaceutico del mismo

Country Status (21)

Country Link
US (3) US11014910B2 (https=)
EP (1) EP3760624A4 (https=)
JP (3) JP7206132B2 (https=)
KR (1) KR102795351B1 (https=)
CN (1) CN111757877B (https=)
AR (1) AR114418A1 (https=)
AU (1) AU2019227770B2 (https=)
BR (1) BR112020016788A2 (https=)
CA (1) CA3087859A1 (https=)
CL (1) CL2020002199A1 (https=)
IL (1) IL276311B2 (https=)
MA (1) MA52427A (https=)
MX (1) MX2020009070A (https=)
MY (1) MY205197A (https=)
PE (1) PE20210123A1 (https=)
PH (1) PH12020551340A1 (https=)
SA (1) SA520420037B1 (https=)
SG (1) SG11202007120UA (https=)
TW (1) TWI805699B (https=)
WO (1) WO2019168096A1 (https=)
ZA (1) ZA202004600B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI805699B (zh) * 2018-03-01 2023-06-21 日商日本煙草產業股份有限公司 甲基內醯胺環化合物及其用途
EP3778593A4 (en) 2018-04-04 2021-12-22 Japan Tobacco Inc. HETEROARYL-SUBSTITUTED PYRAZOLE COMPOUND AND ITS MEDICAL USE
JP7760370B2 (ja) * 2019-09-04 2025-10-27 日本たばこ産業株式会社 慢性腎臓病の治療又は予防方法
US20230119894A1 (en) * 2019-09-04 2023-04-20 Japan Tobacco Inc. Therapeutic or prophylactic method for diabetes using combination medicine
CA3175131A1 (en) 2020-03-19 2021-09-23 Chihiro Okuma Treatment or prevention method for chronic heart failure

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3657282A (en) * 1969-01-23 1972-04-18 Merck & Co Inc Carboxyepoxyethyl-1-phosphonic acid and derivatives
FR2665898B1 (fr) 1990-08-20 1994-03-11 Sanofi Derives d'amido-3 pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
JPH04247081A (ja) 1991-02-01 1992-09-03 Takeda Chem Ind Ltd 5員複素環酸アミド類
FR2692575B1 (fr) 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
US7622471B2 (en) 2003-02-07 2009-11-24 Daiichi Pharmaceutical Co., Ltd. Pyrazole derivatives having a pyridazine and pyridine functionality
AU2004200420A1 (en) 2003-03-11 2004-09-30 Astellas Pharma Inc. Inhibitor of cyclooxygenase
JP2006182648A (ja) 2003-04-08 2006-07-13 Dai Ichi Seiyaku Co Ltd 7員複素環誘導体
WO2004110351A2 (en) 2003-05-14 2004-12-23 Anadys Pharmaceuticals, Inc. Heterocyclic compounds for treating hepatitis c virus
TW200526588A (en) 2003-11-17 2005-08-16 Smithkline Beecham Corp Chemical compounds
TW200526641A (en) 2003-12-26 2005-08-16 Daiichi Seiyaku Co Amidopyrazole derivatives
CN1980665A (zh) 2004-07-07 2007-06-13 默克公司 吡唑酰胺衍生物,包含这些化合物的组合物和使用方法
AU2005305675B2 (en) 2004-11-16 2012-12-13 Jazz Pharmaceuticals Operations Uk Limited New use for cannabinoid
JP2008007405A (ja) 2004-12-07 2008-01-17 Takeda Chem Ind Ltd カルボキサミド誘導体
JP4137956B2 (ja) * 2005-06-08 2008-08-20 日本たばこ産業株式会社 複素環化合物
KR100970294B1 (ko) 2005-06-08 2010-07-15 니뽄 다바코 산교 가부시키가이샤 복소환 화합물
ZA200800142B (en) * 2005-06-08 2009-05-27 Japan Tobacco Inc Heterocyclic compound
WO2007034279A2 (en) * 2005-09-19 2007-03-29 Pfizer Products Inc. C3a antagonists and pharmaceutical compositions thereof
WO2007098826A2 (en) 2006-01-18 2007-09-07 Siena Biotech S.P.A. Modulators of alpha7 nicotinic acetylcholine receptors and therapeutic uses thereof
EP2026798A1 (en) * 2006-04-27 2009-02-25 Solvay Pharmaceuticals GmbH Pharmaceutical compositions comprising cbx cannabinoid receptor modulators and potassium channel modulators
US20080027014A1 (en) 2006-07-28 2008-01-31 Tanabe Seiyaku Co., Ltd. Novel SGLT inhibitors
KR101450356B1 (ko) 2006-11-24 2014-10-15 에이씨 이뮨 에스.에이. 알츠하이머와 같은 아밀로이드 또는 아밀로이드-유사 단백질과 관련된 질환의 치료를 위한 n-(메틸)-1h-피라졸-3-아민, n-(메틸)-피리딘-2-아민 및 n-(메틸)-티아졸-2-아민 유도체
EP2121619A2 (en) 2006-11-24 2009-11-25 AC Immune S.A. Compounds for the treatment of diseases associated with amyloid or amyloid-like proteins
TW200901974A (en) 2007-01-16 2009-01-16 Wyeth Corp Compounds, compositions, and methods of making and using them
JP5583003B2 (ja) * 2007-04-02 2014-09-03 セラコス・インコーポレイテッド ベンジルグルコシド誘導体およびその用途
WO2009091813A1 (en) 2008-01-14 2009-07-23 Wyeth Compounds useful as alpha7 nicotinic acetylcholine receptor agonists
EP2349484A2 (en) 2008-07-15 2011-08-03 Novartis AG Heteroaryl derivatives as dgat1 inhibitors
CN102918034B (zh) 2010-03-30 2015-06-03 维颂公司 多取代芳族化合物作为凝血酶的抑制剂
AR087701A1 (es) * 2011-08-31 2014-04-09 Japan Tobacco Inc Derivados de pirazol con actividad inhibidora de sglt1
KR102727059B1 (ko) * 2015-02-16 2024-11-05 더 유니버서티 어브 퀸슬랜드 설포닐우레아와 관련 화합물 및 그 용도
CN109071454B (zh) * 2016-02-16 2023-02-17 昆士兰大学 磺酰脲和相关化合物及其用途
TWI805699B (zh) * 2018-03-01 2023-06-21 日商日本煙草產業股份有限公司 甲基內醯胺環化合物及其用途
EP3778593A4 (en) 2018-04-04 2021-12-22 Japan Tobacco Inc. HETEROARYL-SUBSTITUTED PYRAZOLE COMPOUND AND ITS MEDICAL USE

Also Published As

Publication number Publication date
CL2020002199A1 (es) 2020-12-18
JP2023026566A (ja) 2023-02-24
MA52427A (fr) 2021-01-06
SA520420037B1 (ar) 2024-07-28
TWI805699B (zh) 2023-06-21
CN111757877A (zh) 2020-10-09
EP3760624A4 (en) 2021-11-03
PH12020551340A1 (en) 2021-05-31
US20190352284A1 (en) 2019-11-21
WO2019168096A1 (ja) 2019-09-06
MY205197A (en) 2024-10-07
US11014910B2 (en) 2021-05-25
CA3087859A1 (en) 2019-09-06
AU2019227770A1 (en) 2020-07-09
RU2020131756A (ru) 2022-03-28
TW202000660A (zh) 2020-01-01
BR112020016788A2 (pt) 2021-01-12
AR114418A1 (es) 2020-09-02
ZA202004600B (en) 2022-03-30
JP2019151627A (ja) 2019-09-12
IL276311A (en) 2020-09-30
JP2025026615A (ja) 2025-02-21
MX2020009070A (es) 2020-10-08
KR102795351B1 (ko) 2025-04-16
IL276311B2 (en) 2023-10-01
IL276311B1 (en) 2023-06-01
US20240174646A1 (en) 2024-05-30
EP3760624A1 (en) 2021-01-06
CN111757877B (zh) 2023-10-27
JP7206132B2 (ja) 2023-01-17
SG11202007120UA (en) 2020-08-28
KR20200128033A (ko) 2020-11-11
US20220064148A1 (en) 2022-03-03
AU2019227770B2 (en) 2023-10-05

Similar Documents

Publication Publication Date Title
PE20210123A1 (es) Compuesto de anillo de metillactama y uso farmaceutico del mismo
CL2022000250A1 (es) Molécula de unión al antígeno multiespecífica que tiene actividad de sustitución de la función de cofactor del factor viii de coagulación de sangre (fviii) y formulación farmacéutica que contiene tal molécula como ingrediente activo (divisional de la solicitud n°202000767)
CL2020002026A1 (es) Inhibidor de fap.
CO2021005226A2 (es) Nuevos compuestos antihelmínticos
CO2019014484A2 (es) Nuevos derivados de azaquinolina
MX2023013194A (es) Compuesto inhibidor de atr que contiene sulfoximina.
CO6382119A2 (es) Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades
DOP2019000275A (es) Nuevos derivados de pirazol bicíclicos
CR20200334A (es) Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas
UY37831A (es) Nuevos derivados de quinolina
CL2020002891A1 (es) Nuevos derivados de quinolina
MX2015011478A (es) Compuestos de amida para el tratamiento de vih.
MX2024005304A (es) Derivado del acido fenilpropionico sustituido y uso del mismo.
AR099632A1 (es) Tratamiento de una infección viral de hepatitis c, que usa una combinación de compuestos
BR112015019412A2 (pt) inibidores de bace1
MX2021004331A (es) Composiciones estables de semaglutida y usos de las mismas.
EA201992272A1 (ru) Ацилированное инсулиновое соединение
CL2019002480A1 (es) Derivados de pirazol como inhibidores de bromodominio.
EA202190398A1 (ru) Конденсированное кольцевое производное, применяемое в качестве ингибитора fgfr4
EA202091835A1 (ru) Замещенные циклоалкилом пиразолопиримидины, обладающие активностью против rsv
PE20181450A1 (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
MX2022004212A (es) Moduladores de atf6 y usos de los mismos.
EA202091341A1 (ru) Пиразолопиримидины, обладающие активностью в отношении респираторно-синцитиального вируса (rsv)
CO2022004572A2 (es) Tratamiento de la diabetes mellitus tipo 2
BR112016007430A2 (pt) 5-aril-1-imino-1-oxo-[1,2,4]tiadiazinas